Treats oropharyngeal and esophageal candidiasis. ANDA 205573, held by Amneal Pharmaceuticals. Itraconazole.
As of Nov 21, 2026, ANDA 205573 (Itraconazole), held by Amneal Pharmaceuticals, was first approved by FDA on Oct 30, 2015, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see CLINICAL PHARMACOLOGY: Special Populations, WARNINGS, and ADVERSE REACTIONS: Postmarketing Experience for more information).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Itraconazole10MG/ML · solution;oral | Itraconazole | Rx |
| Mar 16, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters